Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Systemic Therapy for Melanoma

Publication Date: August 14, 2023

Last Updated: May 16, 2024

Treatment

Neoadjuvant Systemic Therapy

Cutaneous Melanoma Eligible for Resection

Recommendation 1.1.

Neoadjuvant pembrolizumab (maximum of 3 courses of 200 mg once every 3 weeks) followed by resection and adjuvant pembrolizumab (maximum of 15 courses of 200 mg once every 3 weeks) should be offered to patients with clinical and resectable stage IIIB–IV cutaneous melanoma. ( EB , M, B , S )

Systemic Therapy for Melanoma

Treatment

Neoadjuvant Systemic Therapy

Cutaneous Melanoma Eligible for Resection

Recommendation 1.1.

Video

Overview

Title

Authoring Organization